The biological basis for the attenuation of mucositis: The example of interleukin-11

Leukemia

Volumn 13, Issue 6, 1999, Pages 831-834

  Sonis, S ^a   Edwards, L ^a   Lucey, C ^a  

^a NONE

Author keywords

Antieoplastic agents; Interleukin 11; Mucositis; Radiation therapy; Stomatitis; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; INTERLEUKIN 11;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTEREMIA; BACTERIAL INFECTION; CONTROLLED STUDY; GRANULOCYTOPENIA; HAMSTER; HUMAN; MICROORGANISM; MOUTH ULCER; MUCOSA CELL; MUCOSA INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SALIVA; SEPSIS; SHORT SURVEY;

EID: 0032969549     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401441     Document Type: Short Survey

References (42)

1. Sonis ST. Oral complications. In: JF Holland et al (eds). Cancer Medicine, 4th edn. William and Wilkins: Philadelphia, 1997, pp 3255-3264.
2. Bochud P, Eggima P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31.
3. Ruescher TJ, Sodeifi A, Scrivani S, Kaban LB, Sonis ST. The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
4. Feber T. Management of mucositis in oral irradiation. Clin Oncol 1996; 8: 106-111.
5. Rocke L, Loprinzi CL, Lee JK, Kunelsman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72: 2234-2238.
6. Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet 1996; 347: 1691-1692.
7. Epstein JB, Wong FL. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 1994; 28: 693-698.
8. Meredith S, Salter M, Kim R, Spencer S, Wepplemann B, Rodu B et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radial Oncol Biol Phys 1997; 37: 275-279.
9. Ibrahim EM, al-Mulhim FA. Effect of granulocyte-macrophage colony stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol 1997; 14: 47-51.
10. Kannan V, Bapsy PP, Anantha N, Doval DC, Vaithianathan H, Banumathy G et al. Efficacy and safety of granulocyte-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1997; 37: 1005-1010.
11. Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML et al. Evaluation of GM-CSF mouthwash for the prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995; 7: 471-477.
12. Sonis ST, Linquist L, VanVugt A, Stewart AA, Stam K, Qu GY, Iwata KK, Haley JD. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor-β3. Cancer Res 1994; 54: 1135-1138.
13. Sonis ST, Costa JW Jr, Evitts SM, Linquist LE, Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med, Oral Pathol 1992; 74: 749-755.
14. Kahn WB, Shui C, Ning S, Knox SJ. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res 1997; 148: 1-6.
15. Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res 1998; 18: 2203-2210.
16. Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92: 481-484.
17. Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11: 379-382.
18. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis. A randomized double-blind study. Bone Marrow Transplant 1996; 17: 809-812.
19. LeVeque F, Dansey R, Klein B. Use of concurrent oral pilocarpine to treat mucositis during bone marrow transplantation: a pilot study (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A378.
20. Oblon DJ, Paul S, Sturm T, Oblon MB. Anticholinergic therapy reduces the severity of oral mucositis after high dose etoposide (VP16) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A1771.
21. Barasch A, Peterson DE, Tanzer JM, D'Ambrosio JA, Nuki K, Schubert MM et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation recipients. Cancer 1996; 76: 2250-2556.
22. Verdi CJ, Garewal HS, Koening LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg, Oral Med, Oral Pathol 1995; 80: 36-42.
23. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988; 3: 483-493.
24. Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89-95.
25. Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMurray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo controlled double-blind trial (Meeting abstract). Br J Cancer 1995; 72 (Suppl.): 15.
26. Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle I et al. A randomized trail of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997; 79: 2193-2199.
27. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997; 195 (Suppl. 2): 57-61.
28. Loury DJ, Embree J, So W, Fujii C, Steinberg DA, Sonis ST et al. Topical administration of IB-367, a novel antimicrobial peptide, reduces the severity of oral mucositis in 5-FU-treated hamsters (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A257.
29. Sonis AL, Sonis ST. Oral complications of cancer therapy in pediatric patients. J Pedodontics 1979; 3: 12-16.
30. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatoxicity. Oral Oncol 1998; 34: 39-43.
31. Hall PD, Benko H, Hogan KR, Stuart RK. The influence of serum tumor necrosis factor-α and interleukin-6 concentrations on non-hematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 1995; 23: 1256-1260.
32. Jaenke RS, Robbins MEC, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. Capillary endothelium. Target site of renal radiation injury. Lab Invest 1993; 68: 396-405.
33. Sonis S, Edwards L, Lucey C, Login G, Yamakawa M, Dorner A. The biological basis for interleukin-11 attenuation of oral mucositis. Proceedings of the 11th Symposium Molecular Biology of Hematopoiesis 1998; Abstr. 117.
34. Gifford GE, Lohmann-Matthes ML. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor by bacterial lipopolysaccharides. J Natl Cancer Inst 1987; 78: 121-124.
35. Goldman SJ. Preclinical biology of interleukin-11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995; 13: 462-471.
36. Peterson RL, Bozza MM, Dorner AJ. Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation. Am J Patbol 1996; 149: 895-902.
37. Maier R, Ganu V, Lotz M. Interleukin-11, an inducible cytokine in human articular chrondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases. J Biol Chem 1993; 268: 21527-21532.
38. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157: 3627-3634.
39. Orazi A, Du A, Yang Z, Kashai M, Williams DA. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 1996; 75: 33-42.
40. Sonis ST, Van Vugt AG, McDonald J, Dotoli E, Schwertschlag U, Szklut P et al. Mitigating effects of interleukin-11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997; 9: 605-612.
41. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Patbol 1990; 69: 437-443.
42. Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P, Keith J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Oral Oncol Eur J Cancer 1995; 31B: 261-266.